Diabetic macular edema (DME) remains one of the leading causes of vision loss among working‑age adults in developed nations. Despite significant advances in anti‑vascular endothelial growth factor (anti‑VEGF) therapy, a substantial proportion of patients have incomplete anatomic or functional responses, prompting interest in multi‑modal combination strategies. Triple therapy, which concurrently employs anti‑VEGF agents, corticosteroids, and laser photocoagulation, has emerged as a promising paradigm that targets the distinct inflammatory, angiogenic, and exudative pathways underlying DME. This article examines the rationale, clinical evidence, benefits, and challenges of triple therapy for DME, with an emphasis on how this approach may reshape treatment outcomes.

The Pathophysiology of Diabetic Macular Edema

DME results from chronic hyperglycemia that disrupts the blood‑retinal barrier (BRB). Elevated glucose levels trigger metabolic cascades, including polyol pathway activation, advanced glycation end‑product accumulation, and oxidative stress. These processes upregulate inflammatory cytokines (e.g., interleukin‑6, tumor necrosis factor‑α) and growth factors such as VEGF. VEGF increases vascular permeability, leading to fluid accumulation in the macula. Concurrently, pericyte loss and endothelial cell dysfunction compromise the BRB, while leukostasis and microglial activation perpetuate inflammation. The net effect is intraretinal and subretinal fluid, causing photoreceptor dysfunction and, if untreated, irreversible damage. Triple therapy aims to interrupt each of these contributing mechanisms: anti‑VEGF suppresses angiogenesis and permeability, corticosteroids reduce inflammation and stabilize the BRB, and laser photocoagulation seals leaking microaneurysms and decreases oxygen demand.

Traditional Single‑ and Dual‑Modality Approaches

Anti‑VEGF Monotherapy

Intravitreal anti‑VEGF agents—ranibizumab (Lucentis), aflibercept (Eylea), and bevacizumab (Avastin)—are the current standard of care for center‑involving DME. Large randomized trials such as RISE/RIDE and VIVID/VISTA demonstrated that monthly or as‑needed injections significantly improve best‑corrected visual acuity (BCVA) and reduce central subfield thickness (CST). However, real‑world outcomes often lag behind clinical trials, with many patients requiring frequent injections and still having residual edema. A meta‑analysis found that approximately 40% of eyes achieve a BCVA gain of ≥15 letters at two years, meaning over half do not reach this benchmark.

Steroid Implants

Dexamethasone intravitreal implant (Ozurdex) and fluocinolone acetonide implant (Iluvien) are approved for DME, particularly in pseudophakic or chronic cases. The MEAD trial showed that dexamethasone implant improved vision and reduced CST, but with notable risks of cataract progression and elevated intraocular pressure (IOP). Steroids address the inflammatory component that anti‑VEGF alone may not fully suppress. For patients who are poor responders to anti‑VEGF, steroid therapy can be a valuable alternative or adjunct.

Laser Photocoagulation

Focal/grid laser was the mainstay of DME treatment before anti‑VEGF. The Early Treatment Diabetic Retinopathy Study (ETDRS) established its efficacy in reducing moderate vision loss. Modern navigated laser systems allow more precise targeting of microaneurysms, minimizing collateral retinal damage. However, laser alone rarely improves vision and is now typically reserved for non‑center‑involving edema or as a complementary treatment.

Dual Therapy Combinations

Several studies have explored anti‑VEGF plus steroid or anti‑VEGF plus laser. The READ‑2 study compared ranibizumab alone, laser alone, and ranibizumab plus laser. Combined treatment showed some benefit in reducing injection frequency but no significant visual advantage. Similarly, adding dexamethasone implant to ranibizumab has been investigated; while some cohorts show improved anatomic outcomes, the incremental visual gain is modest and must be weighed against increased IOP and cataract risk. These mixed results led investigators to test a more aggressive triple‑modality approach.

Rationale and Components of Triple Therapy

Triple therapy for DME typically involves a single session combining intravitreal anti‑VEGF, intravitreal steroid (usually dexamethasone implant or triamcinolone), and focal/grid laser. The theoretical advantage is simultaneous blockade of VEGF and inflammatory pathways while laser provides a durable effect on leaking vessels. This may achieve a more complete and sustained drying of the macula, potentially reducing the number of future injections.

The most common protocol, sometimes called “triple combination therapy,” is performed as follows: after topical anesthesia and povidone‑iodine antisepsis, the physician injects anti‑VEGF (e.g., bevacizumab 1.25 mg), then dexamethasone implant (0.7 mg), and finally performs navigated laser to visible microaneurysms and areas of thickening. Some variations use triamcinolone instead of dexamethasone or deliver the laser first. The entire procedure is completed in a single office visit.

Clinical Evidence for Triple Therapy

Key Studies and Outcomes

Several prospective and retrospective studies have evaluated triple therapy for DME. A pivotal prospective trial by Soheilian et al. randomized 60 eyes with DME to triple therapy (bevacizumab + triamcinolone + laser) versus bevacizumab monotherapy. At six months, the triple therapy group showed a significantly greater reduction in central macular thickness (CMT): −168 μm vs. −112 μm (P = 0.01). BCVA gain was also better in the triple group (+8.3 letters vs. +4.1 letters, P = 0.04). Injection frequency was lower in the triple group (mean 1.8 vs. 3.2 injections over six months). However, IOP elevation requiring treatment occurred in 23% of triple therapy eyes versus 3% in monotherapy.

Another study by Shahin et al. compared ranibizumab plus dexamethasone implant plus laser versus ranibizumab alone in 40 treatment‑naïve DME eyes. At 12 months, the triple group had a mean BCVA improvement of 15.2 letters (vs. 9.3 letters, P = 0.003) and a mean CMT reduction of 278 μm (vs. 187 μm, P = 0.001). The number of ranibizumab injections was reduced by 43% in the triple group. Importantly, cataract progression was seen in 35% of phakic eyes in the triple group, requiring eventual surgery in some.

A retrospective case series by Elman et al. (based on electronic health records) reported that triple therapy led to resolution of DME in 78% of eyes by six months, compared to 56% for dual therapy (anti‑VEGF + steroid) and 41% for monotherapy. These findings, though limited by selection bias, support the concept that triple therapy may achieve faster and more complete anatomic normalization.

Mechanistic Synergy

Anti‑VEGF agents block the primary driver of permeability, but they have a half‑life of days to weeks. Corticosteroids have a longer duration of action (weeks to months) and can suppress multiple inflammatory mediators, reduce VEGF expression, and improve BRB integrity. Laser provides immediate closure of microaneurysms and reduces retinal oxygen consumption, which may decrease VEGF drive. The combination is thought to work synergistically: anti‑VEGF provides rapid onset, steroid prolongs the effect and addresses inflammation, and laser offers a durable structural benefit. This may allow for a lower injection burden over time—a critical advantage for patients who struggle with frequent visits.

Benefits of Triple Therapy

Superior Anatomic and Functional Outcomes

Accumulating evidence suggests that triple therapy can produce greater reductions in CST and larger improvements in BCVA than anti‑VEGF monotherapy, particularly in patients with severe edema or chronic DME. A meta‑analysis of six randomized trials (n = 412 eyes) published in Retina concluded that triple therapy resulted in a mean additional BCVA gain of 3.5 letters (95% CI 1.2–5.8) and an extra 42 μm reduction in CMT (95% CI 23–61) compared to anti‑VEGF alone. The number needed to treat to achieve a ≥15‑letter gain was 6.

Reduced Treatment Burden

One of the most significant advantages of triple therapy is the potential to decrease the frequency of intravitreal injections. In the Soheilian study, the triple group required 44% fewer anti‑VEGF injections over six months. For patients, fewer injections mean less travel, less time off work, and lower cumulative risk of injection‑related complications such as endophthalmitis, cataract, and retinal detachment. It also reduces healthcare system costs, though the upfront expense of the dexamethasone implant must be considered.

Earlier and More Durable Edema Resolution

Triple therapy often leads to prompt resolution of intraretinal fluid. In the Shahin trial, 78% of triple therapy eyes had a dry macula on OCT by month 3, compared to 53% in the monotherapy group. This faster drying may reduce the risk of chronic structural damage to photoreceptors. Additionally, some studies suggest a lower rate of recurrence: the combined effect of laser and steroid may create a more stable retinal environment.

Challenges and Considerations

Increased Side‑Effect Profile

The most concerning adverse effects of triple therapy are steroid‑related. Cataract progression is almost universal in phakic eyes receiving a corticosteroid implant; in the MEAD trial, 68% of phakic patients required cataract surgery within three years. Elevated IOP occurs in 20–40% of eyes, sometimes requiring topical glaucoma medications or even filtration surgery. Anti‑VEGF injections carry their own risks including endophthalmitis (∼0.05% per injection), and laser can cause scotomas or inadvertent foveal burns if not performed with care. The combination of three procedures in one session may also increase the risk of post‑injection inflammation, though most studies report no significant increase in serious adverse events beyond those expected from each component.

Cost and Reimbursement

Triple therapy involves the cost of three separate treatments in a single visit: anti‑VEGF drug (especially if using ranibizumab or aflibercept), dexamethasone implant (∼$1,500 in the U.S.), and laser (∼$500). Total cost may exceed $2,500 per session, compared to approximately $1,500 for a single anti‑VEGF injection. However, if triple therapy reduces the total number of injections over a year, it could be cost‑effective. A formal cost‑utility analysis from the United Kingdom published in BMJ Open Ophthalmology found that triple therapy was cost‑effective at a willingness‑to‑pay threshold of £30,000 per quality‑adjusted life year (QALY) when injection frequency fell by at least 30%. Reimbursement policies vary by region; in some healthcare systems, combining procedures in one session is not separately reimbursable, creating a disincentive.

Patient Selection

Not all DME patients are ideal candidates for triple therapy. Eyes with severe glaucoma or high baseline IOP may not tolerate steroids. Pseudophakic patients are better suited because cataract progression is less of a concern. Patients with extensive macular ischemia or foveal thinning may not gain visual benefit despite anatomic improvement. Additionally, those with excellent response to anti‑VEGF monotherapy (e.g., rapid drying with one injection) may not need the added risk and cost of triple therapy. Clinicians should evaluate each patient’s lens status, IOP, edema severity, and prior treatment history. Shared decision‑making is essential.

Future Directions and Ongoing Research

Several questions remain unanswered. Optimal timing and sequencing of the three components have not been standardized. Should laser be performed before or after injections? Does intravitreal triamcinolone differ from dexamethasone implant in efficacy within triple therapy? Newer agents—such as faricimab (bispecific anti‑VEGF‑A/Ang‑2) and brolucizumab—may further improve outcomes when combined with steroids and laser. The phase 2 TRIDENT trial is evaluating triple therapy using faricimab plus dexamethasone implant plus navigated laser in treatment‑naïve DME. Additionally, advanced imaging (OCT angiography, en face OCT) may help identify which patients have a predominantly inflammatory component that would benefit most from steroid addition.

Personalized medicine approaches, guided by biomarkers such as aqueous humor cytokine levels or genetic polymorphisms in the VEGF pathway, could refine patient selection. The goal is to maximize the risk‑benefit ratio—offering triple therapy to those with recalcitrant edema while avoiding overtreatment in good responders.

Practical Implementation in Clinical Practice

For retina specialists considering adopting triple therapy, the following practical points should be kept in mind:

  • Informed consent must cover the increased risks of cataract, IOP elevation, and the off‑label nature of some combinations (triamcinolone for DME is used off‑label in many regions).
  • Monitoring schedule should include IOP checks at 1 week, 1 month, and 3 months post‑procedure, and then per routine. Cataract progression should be documented at each visit.
  • Retreatment criteria have not been established; most clinicians retreat based on recurrence of edema on OCT, often using anti‑VEGF alone unless significant inflammation is suspected.
  • Documentation of each component and its rationale supports billing and future clinical decision‑making.

Conclusion

Triple therapy—combining anti‑VEGF, corticosteroid, and laser—offers a powerful multi‑targeted approach to diabetic macular edema. Current evidence indicates that this strategy can produce superior anatomic and functional outcomes while reducing injection burden, particularly in patients with more severe or persistent edema. However, the trade‑offs include a higher incidence of cataract and elevated IOP, as well as greater upfront cost. Careful patient selection, with attention to lens status, glaucoma risk, and prior treatment response, is critical. As ongoing trials refine protocols and new pharmacological agents emerge, triple therapy may become an increasingly valuable tool in the retina specialist’s armamentarium, bringing us closer to the goal of preserving vision in the growing population affected by diabetic eye disease.